Searched for
ABRAXANE ALTERNATIVE
Cipla gets USFDA nod for generic cancer drugCipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable suspension (100...- Fundamental Radar | Cipla upgraded to “buy” on 5 major growth tailwinds: Motilal OswalCipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...
- 3 stocks Nithya Balasubramanian is bullish on from pharma sectorWe have seen some players recall some products. We have seen some players file bankruptcies. So these will therefore create opportunities f...
- Why Nithya Balasubramanian is betting on Sun Pharma & Cipla, avoiding 2 others“When it comes to pharma we are not seeing secular growth. While India can be a secular growth story, we believe the US would not be and th...
Load More